Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia

Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia

<b>Background/Objectives</b>: Anti-CD20 monoclonal antibodies combined with alkylator-based chemotherapy enhance survival in chronic lymphocytic leukemia (CLL). However, the risks of infection and bone marrow suppression may mean that new, targeted therapies are more appropriate for some...

Full description

Saved in:
Bibliographic Details
Main Authors: Tong-Yoon Kim, Gi-June Min, Young-Woo Jeon, Seung-Ah Yahng, Seok-Goo Cho, Jong-Mi Lee, Myungshin Kim, Ki-Seong Eom
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Biomedicines
Subjects:
chronic lymphocytic leukemia
bicytopenia B-cell
chemotherapy
fludarabine
cyclophosphamide
rituximab
Online Access:https://www.mdpi.com/2227-9059/13/1/194
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/13/1/194

Similar Items